We spoke with Jim Zukin, the CEO & Chairman of Zukin Certification Services, and former Co-Founder of Houlihan Lokey, about his new product – the Reasonable Basis Review, or “RBR”.
The Reasonable Basis Review is intended to help SPAC sponsors follow SEC guidance as it relates to financial projections, but also allow their target companies to have financial projections reviewed and validated by a trusted third-party.
Jim goes into why he thinks the RBR will be widely adopted by SPACs as a result of the current SEC SPAC rule proposal. But, he also believes the RBR will have a large presence in the wider M&A landscape.
Give it a listen
An In-Depth Look at SPAC Activity Through the First Half of 2024 Below is a summary of the year-to-date SPAC performance. Q2-2024 started off slow with the usual April doldrums, but SPAC activity has since picked up speed. In fact, June was the first month where many in SPACLand were expressing cautious optimism thanks to...
Terms Tracker for the Week Ending June 28, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. As mentioned previously, this is going to an abbreviated summary this week since we’re hard at work summarizing the quarter and the first half of...
July is the first month in some time with a 1-to-1 overlap between the companies and the sponsors that are being released from lockups. Overall, this group is currently trading at a split-adjusted median share price of $1.10, but that doesn’t mean doom and gloom for all. PSQ Holdings (NYSE:PSQH), which launched as a commerce...
The Nasdaq announced it has halted trading for Canna-Global (NASDAQ:CNGL), and not for any of the usual reasons, but rather for a request of information following a particularly unusual issuance of shares. Essentially, Canna-Global and underwriter EF Hutton agreed to retire the $8 million deferred underwriting fee the SPAC still owed it at close. EF...
Arogo Capital (NASDAQ:AOGO) has entered into a definitive agreement to combine with cannabis firm Ayurcann (CSE:AYUR) at an enterprise value of $210 million. Ayurcann sells cannabis products primarily direct-to-consumer in Canada and is a leading brand in Ontario. The deal is expected to be completed in the second half of 2024. Transaction Overview Arogo has...